CMCaren Mburu

Caren Mburu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Caren Mburu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Missed Opportunities to Prevent Mortality Among Youth Living With HIV: Insights From Verbal Autopsies and Clinical Record Reviews

    by Hellen Moraa, Irene N. Njuguna, Caren Mburu, Grace John-Stewart, Dalton C. Wamalwa

    We conducted verbal autopsies and abstracted medical records of deceased youth living with HIV to identify missed opportunities for intervention. Of 60 deceased youth, the median age was 20 years, 65% acquired HIV perinatally and 67% were female. Overall, 55% of deaths occurred in hospitals, and 74% had adherence challenges. Mental health challenges and viral failure were key contributors to mortality.

  • Mortality and Loss to Follow-Up Among Adolescents and Young Adults Attending HIV Care Programs in Kenya

    by Caren Mburu, Irene Njuguna, Jillian Neary, Cyrus Mugo, Hellen Moraa, Kristin Beima-Sofie, Alvin Onyango, Laura Oyiengo, Barbra A. Richardson, Grace John-Stewart, et al.

    Mortality and loss to follow-up (LTFU) among adolescents and youth living with HIV (AYLHIV) remain high. We evaluated mortality and LTFU during the test and treat era. We abstracted medical records of AYLHIV for 10–24 years between January 2016 and December 2017 in 87 HIV clinics in Kenya. Using competing risk survival analysis, we compared incidence rates and determined correlates of mortality and LTFU among newly enrolled [p < 0.001). Incidence of mortality and LTFU per 100 person-years were 2.32 [95% confidence interval (CI): 1.64–3.28] and 37.8 (95% CI: 34.7–41.3), respectively, among new enrollments and 1.22 (95% CI: 0.94–1.59) and 10.2 (95% CI: 9.3–11.1), respectively, among those on ART for ≥2 years. New enrollments had almost twice higher risk of mortality [subdistribution hazard ratio (sHR) 1.92 (1.30, 2.84), p = 0.001] and sevenfold higher risk of LTFU [sHR 7.71 (6.76, 8.79), p < 0.001] than those on ART for ≥2 years. Among new enrollments, mortality was higher in males and those with World Health Organization (WHO) stage III/IV disease at enrollment, and LTFU was associated with pregnancy, older age, and nonperinatal acquisition. Female sex and WHO stage (I/II) were associated with LTFU among those on ART for ≥2 years. During the study period from January 1, 2016, to December 31, 2017, the mortality incidence observed did not demonstrate improvement from earlier studies despite universal test and treat and better ART regimens. This trial was registered with ClinicalTrials.gov, NCT03574129.